Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Goldman Sachs Group Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.97 (market cap $31.07B), while Goldman Sachs Group Inc trades at $882.23 (market cap $259.70B). The key difference: Goldman Sachs Group Inc is far larger — about 8.4× GE HealthCare Technologies Inc. Common Stock's market cap, and Goldman Sachs Group Inc pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| GEHC | GS | |
|---|---|---|
Market Cap | $31.07B | $259.70B |
Volume | 3,443,020 | 4,939,526 |
Sector | Health | Financials |
52-Week High | $88.16 | $1.15K |
52-Week Low | $59.48 | $744.60 |
Enterprise Value | $39.53B | $263.03B |
Dividend Yield | 0.23% | 2.24% |
Typical Hold Time | — | 100 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Goldman Sachs (GS) trades at $891.91, down 0.23% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q3 2026) and improving profitability (net margin 31.68%, ROE 18.33%). Revenue growth accelerated to $58.28B in 2025 with guidance targeting $70B. Recent news highlights AI expansion and wealth management growth, though Q3 FICC business may soften.
GS presents a compelling value opportunity with attractive valuation (P/E 13.77) and 40% analyst buy ratings. Upside to $1,160 consensus target offers ~30% potential, supported by dividend growth and operational efficiency. Risks include market volatility, competitive pressures, and execution on AI/wealth management expansion. The balance sheet remains robust with $122B equity despite negative operating cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
